Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Busulfan in Relapsing acute myeloid leukemia: NCT06869265 Clinical Landscape Report 2026
16 October 2026
NCT06869265 clinical landscape for Relapsing acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Methotrexate Sodium in Arthritis, Psoriatic: NCT06870500 Clinical Landscape Report 2026
16 October 2026
NCT06870500 clinical landscape for Arthritis, Psoriatic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LCAR-AIO(Legend Biotech) in Neuromyelitis Optica: NCT06869278 Clinical Landscape Report 2026
16 October 2026
NCT06869278 clinical landscape for Neuromyelitis Optica: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SHR-1139 in Plaque psoriasis: NCT06875934 Clinical Landscape Report 2026
16 October 2026
NCT06875934 clinical landscape for Plaque psoriasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ocrelizumab in Multiple Sclerosis, Secondary Progressive: CTRI/2025/03/082143 Clinical Landscape Report 2026
16 October 2026
CTRI/2025/03/082143 clinical landscape for Multiple Sclerosis, Secondary Progressive: endpoints, sponsor, phase, geography, readouts, asset context and devel…
9 min read
Fludarabine Phosphate in Recurrent Acute Leukemia: NCT06871410 Clinical Landscape Report 2026
16 October 2026
NCT06871410 clinical landscape for Recurrent Acute Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sirolimus in Relapse multiple myeloma: NCT06876142 Clinical Landscape Report 2026
16 October 2026
NCT06876142 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Teclistamab in Relapse multiple myeloma: NCT06880601 Clinical Landscape Report 2026
16 October 2026
NCT06880601 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CLL1 and CD38 dual-target CAR-T(Gracell Biotechnology Shanghai) in Acute Myeloid Leukemia: NCT06880354 Clinical Landscape Report 2026
16 October 2026
NCT06880354 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tofacitinib Citrate in Dermatitis, Atopic: NCT06880276 Clinical Landscape Report 2026
16 October 2026
NCT06880276 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti-BCMA CAR-T(Institute of Hematology & Blood Diseases Hospital) in Multiple Myeloma: NCT06880393 Clinical Landscape Report 2026
16 October 2026
NCT06880393 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Arsenic Trioxide in Acute Promyelocytic Leukemia: NCT06882031 Clinical Landscape Report 2026
16 October 2026
NCT06882031 clinical landscape for Acute Promyelocytic Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.